Psoriatic Inflammation Markers Predictive of Response to Adalimumab

Inclusion Criteria: * Chronic plaque psoriasis involving at least 10% of body surface area, with a PASI score \>10, * Negative pregnancy test for women of childbearing potential, and use of an effective method of contraception, * Pretreatment assessment to identify contraindications to anti-tumor necrosis factor-alpha therapy (chest x-ray and Intradermal reaction (detection of latent tuberculosis), * Anti-tumor necrosis factor-alpha treatment with adalimumab has been prescribed Exclusion Criteria: * Classical exclusion criteria for adalimumab therapy (hypersensitivity to the product, severe heart failure, abscess, tuberculosis or other opportunistic infection), * History of demyelinating disease, any unstable medical condition, patients with recurrent serious infections , history of cardiovascular or cerebrovascular disease , history of cancer * Patients not having tuberculosis prophylaxis as per local guidelines for latent tuberculosis, or patients non-treated active tuberculosis * Ongoing pregnancy or breastfeeding * Absence of written consent, * Prior treatment with one of the following anti-psoriatic treatments: biologics during the 3 months prior baseline visit, other systemic treatment during the 4 weeks prior baseline visit or topical therapy during the 2 weeks prior baseline visit.